132 related articles for article (PubMed ID: 37608072)
1. Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma.
Malard F; Battipaglia G; Gaugler B; Siblany L; van de Wyngaert Z; Bonnin A; Duléry R; Banet A; Stocker N; Ricard L; Brissot E; Mohty M
Bone Marrow Transplant; 2023 Nov; 58(11):1275-1278. PubMed ID: 37608072
[No Abstract] [Full Text] [Related]
2. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
3. A rare case of interstitial pneumonitis after tandem high-dose melphalan conditioning and autologous stem cell transplantation in multiple myeloma.
Buxhofer-Ausch V; Ruckser R; Kier P; Habertheuer KH; Zelenka P; Tatzreiter G; Ausch C; Schmid I; Hruby W; Reiner-Concin A; Sebesta C; Ogris E; Hinterberger-Fischer M; Hinterberger W
Eur J Haematol; 2004 Aug; 73(2):143-6. PubMed ID: 15245515
[TBL] [Abstract][Full Text] [Related]
4. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
5. Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
Apolito V; Giaccone L; Ferrero S; Larocca A; Cavallo F; Coscia M; Beggiato E; Butera S; Martella F; Dainese C; Cetani G; Scaldaferri M; Cattel F; Boccadoro M; Ferrero D; Bruno B; Cerrano M
Ann Hematol; 2020 Sep; 99(9):2197-2199. PubMed ID: 32661577
[No Abstract] [Full Text] [Related]
6. Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
Katzel JA; Mazumder A; Jagannath S; Vesole DH
Clin Lymphoma Myeloma; 2006 Sep; 7(2):151. PubMed ID: 17026829
[No Abstract] [Full Text] [Related]
7. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
Chen J; Seabrook J; Fulford A; Rajakumar I
J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
[TBL] [Abstract][Full Text] [Related]
8. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
9. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
10. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
11. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.
Srour SA; Milton DR; Bashir Q; Nieto Y; Saini N; Daher M; Ramdial J; Im J; Hosing C; Delgado R; Manasanch E; Lee HC; Thomas S; Kaufman G; Patel K; Popat U; Weber D; Orlowski R; Shpall E; Champlin RE; Qazilbash MH
Haematologica; 2021 Dec; 106(12):3211-3214. PubMed ID: 34407606
[No Abstract] [Full Text] [Related]
12. Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation.
Sahin U; Soydan E; Gokmen A; Ozcan M; Arslan O
Bone Marrow Transplant; 2021 Jan; 56(1):7-8. PubMed ID: 32848191
[No Abstract] [Full Text] [Related]
13. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
Harousseau JL; Moreau P
N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
[No Abstract] [Full Text] [Related]
14. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
15. Optimizing high dose melphalan.
Shah G; Giralt S; Dahi P
Blood Rev; 2024 Mar; 64():101162. PubMed ID: 38097487
[TBL] [Abstract][Full Text] [Related]
16. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
20. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
